Information Provided By: 
Fly News Breaks for June 27, 2019
VRCA
Jun 27, 2019 | 10:41 EDT
H.C. Wainwright analyst Oren Livnat raised his price target for Verrica Pharmaceuticals to $23 from $20 after the company announced "positive results" of the open-label Phase 2 trial of VP-102, topical cantharidin drug-device combination, in common warts. The analyst says his Buy rating and prior target were entirely based on VP-102 for molluscum contagiosum. He sees around $220M in peak warts sales.
News For VRCA From the Last 2 Days
There are no results for your query VRCA
